Selling, Cold Calling, and Follow-Up Are Not Dirty Words

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

The coaching and mentoring universe is divided between those who think that selling, cold calling, and follow-ups are dirty words. They’re likely to proselytize that if you do not have a warm referral, you are wasting your time. The other camp (where I live) supports finding partners based on the fit of product and stage of development and reaching out until you book that meeting or are told, “No.” Life Science Nation created the RESI conference to be a vehicle to make this happen, based on fit – the other “warm referral.”

Opportunity abounds in the golden age of life science with new tools and technologies adding to the dynamic, but we’re also seeing startups fail faster, and therefore pivot, restart, and draw a straighter line to viable targets and products. I hear frequently that the magic combination is being smart and lucky, but somewhere in the middle of being smart and lucky is determination, commitment to hard, tedious work, and navigating the path to a new product. This is the case for founders taking their companies from regional to global and finding investors and licensing partners that are a fit.

RESI is a conference designed for these entrepreneurs to flourish. It’s frustrating to see partnering events with little vetted investors or licensing partners, but rather services providers wanting to charge for their partnering services. These other partnering events are more of a social gathering for reconnecting business acquaintances, which makes it a challenge in choosing the right event for you. None of this is inherently wrong, but the current need is for real vetted partners who are looking to fulfil investment mandates and product pipelines.

The early-stage marketplace is heating up with growing buy-side players seeking these startups. Join us for Digital RESI, June 7-9 and mark your calendar for the first in-person RESI since 2020 – RESI Boston, September 21-22.

AI & Longevity at RESI

By Caitlin Dolegowski, Marketing Specialist, LSN

The Redefining Early Stage Investments (RESI) conference series proudly highlights active investors, early-stage founders, and industry leaders advancing drugs, devices, diagnostics, and digital health. RESI is unique in its focus on early-stage life science and healthcare, but in recent years, has gone even further to cut out space specifically for artificial intelligence (AI) and age-tech innovation. To do this, RESI conferences feature specialized content for startups and strategic partners in these industries through dedicated panels and pitch competitions.

Innovative advancements within these industries and a deep dive into insights around how to navigate the early-stage investment ecosystem specific to conversations happening in AI and Longevity arenas are a major addition and highlight at RESI. Panels provide discussions with investors, industry experts, entrepreneurs, and strategic partners answering questions about early-stage fundraising and age-tech and AI innovation.

View sample panel sessions from Digital RESI March:

LONGEVITY

Digital Health & Wellness
Silver-Tech Focusing on Preventative Care
According to the US Census Bureau, the 65+ population grew by 34% since 2010. These seniors are prioritizing preventative care and the market is responding with products and services focused on staying healthy, specifically those focused on daily exercise, diet, and other factors impacting independence and longevity. How can startups in this booming industry stand out to investors?


AI

Defining AI Investment
AI-Exclusive Investors Share Their Perspectives
Hear from leaders investing exclusively in AI products across drugs, devices, diagnostics, and digital health. Learn more about what AI-exclusive investors have to offer healthtech startups. Learn what entrepreneurs can gain from partnerships that understand their tech and how to take it to the next level.

The lens on age-tech and AI continues at our next conference, Digital RESI, June 7-9. The focus on these markets will include panel topics:

LONGEVITY

Tuesday, June 7 – 2PM EDT | The Neuroscience of Aging
Aging Impact on the Nervous System

Age-tech startups are addressing negative impacts of neurological aging, such as cognitive decline, dementia, and Alzheimer’s. The goal of many of these early-stage companies is to stimulate neurogenesis and enhance brain plasticity to combat these conditions.

Thursday, June 9 – 11 AM EDT – Age-Tech Care Management
Technology Improving the Lives of Older Adults

Older adults are looking to age-tech to provide freedom, medical access & adherence, safety, wellness and even companionship later in life. Age-tech allows seniors, and their caregivers make personalized choices about their own aging journeys. Hear from investors specializing in longevity innovation.


AI

Wednesday, June 8 – 11 AM EDT – AI vs. Life Science
Which Comes First in Early-Stage Investment?

How to prioritize tech-first vs. biology models? How can each model leverage their position in the industry and be successful in the early stage? How can startup founders balance the “bio” and “tech” and highlight their strengths to investors? What are some strategies to help fundraising executives target the right investors for their company and pivot their pitch to each?

Thursday, June 9 – 2 PM EDT – Team, Tech, & Traction in Early-Stage AI
Building Your Startup as a Triple Threat

Early-stage investors will take a chance on a team, tech, or traction. It’s rare to find all three in a company seeking Seed to Series B funding. This discussion will explore the value of each to help early-stage startups highlight their unique assets and improve their position in weaker areas.

Register by April 15 to save $300 with our Super Early Bird rates.

The Angel on Your Shoulder

By Megan Rychwa, Investor Research Analyst, LSN

Anyone embroiled in early-stage fundraising understands the need for solid advice and warm introductions, especially when approaching angel investors and family offices – your own shoulder angel to guide your progress. These investor groups are popular at Redefining Early Stage Investments (RESI) conferences because they offer insights to founders on how to connect and engage with these types of investors.

When it comes to approaching family offices and angels, your network is everything. Faz Bashi of Life Science Angels said at RESI June 2021 “BYNBYNI – build your network before you need it.” As a life science start-up, getting to know the members within an angel group or family office, connecting via LinkedIn, going to events hosted by the angel group or family office and conferences like RESI, and building your network before even asking for money is going to set you apart from other startups. When you are known within the networks, the angels will talk to one another and can provide referrals and deal flow, giving you a warm call to the investor you want to meet with. Cold calls are not an efficient way to connect with investors in general, but especially not with angels and family offices. The gatekeepers may turn you down before you can even pitch your company.

Many angels and family offices have a vast network, and Charles Cameron of Hub Angels Investment Group told his panel at RESI September 2021 that if you cannot get a referral through the network, you are not connected and you are not the right person for the job. Since COVID, your network is even more critical, and you want to be well-connected before even thinking about raising money. Charles explained, “Use the network, get a referral in, do it early, early, and often. I love when people keep me updated before they need the money… Here is an update on the company and I have watched them over time, and you suddenly are building a relationship with that person of trust and insight.” Find a contact and get into the network of angels and family offices you are targeting, and keep people informed on your company’s technology and successes and do it before you need money, so you are already well-known and trusted.

Another key factor in approaching angels and family offices is preparedness. The investors within these groups do a lot of due diligence and research on your company, they ask you to do the same. When approaching an investor, going on their website can make you as an entrepreneur stand out; know their investment criteria, know their portfolio companies, and keep up-to-date with the latest news on the group. Nadav Shimoni of Arkin Holdings said at RESI June 2021 that he expects entrepreneurs to go through their website and portfolio and come to the table saying, “I know this is the type of technologies that get you excited because you’ve invested in it, I really like this blog post you’ve shared, and we are doing something similar.” This shows that they are diligent in the process and will be diligent as a company.

Some angel and family office groups, such as MidAtlantic Bio Angels, have office hours where, before asking for any money at all, a startup can come in with an idea or the preliminary stages of their company and pitch to investors for feedback and advice, so they are ready for the future when they are pitching for money. Doing this builds a relationship within the group early on and if that relationship continues throughout the preliminary stages of the company, that trust has been built and maintained which helps get to the investment stage much easier through connections and networking.

Building your network is the key to success with connecting with angels and family offices, and events like RESI make doing that easier than ever before. When you have built a solid network, that foundation gives your company a lot more credibility and trustworthiness to investors who invest out of their own pockets. Let these principles guide your outreach like a shoulder angel so you can be ready when the real ones come knocking.

Top 10 Challenges for Startups Raising Capital and Seeking Licensing Deals

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the LSN Partnering Conference Series

Check out a recent list of the top challenges startups face when entering the early-stage fundraising arena. Each challenge is linked to an article tackling these and similar issues.

  1. Migrating from regional mindset to global partnering arena
  2. Understanding that deals take 9-18 months and identifying vehicles that can assist in partnering campaigns early
  3. Defining and understanding their competitive landscape
  4. Compiling a global target list (GTL) that is a fit for product and stage of development
  5. Understanding the cost of launching and executing a global partnering campaign ($60K-$90K)
  6. Developing branding and messaging that highlights unique company value that is clear, concise, and easy to understand
  7. Implementing a CRM to activate and organize global campaign, which includes ongoing curation of partner list, outreach initiatives, and tracks status and to-do list for all meetings
  8. Hitting the road with phone and email canvassing, as well as traveling to conferences to engage partners
  9. Learning the art of follow-up (99% of all startups fail here)
  10. Learning how to efficiently partner at a partnering conference

Life Science Nation is committed to facilitating well-fitting meetings between founders with innovative assets and the capital and channel partners who seek them. Join us for one of our free fundraising bootcamps to learn about the products and services we offer to the startup community in life science and healthcare.

Preparing to Pitch at RESI 
  • Alexander Vassallo, Manager, Business Development, Life Science Nation
The Innovator’s Pitch Challenge (IPC) is an opportunity for early-stage companies to gain additional exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session. This bootcamp will walk through the process of preparing your pitch materials and what to expect in a live pitch session, including frequently asked questions from investor judges.

Fundraising 101: Avoiding Pitfalls and Improving the Odds

  • Karen Deyo, Director, Investor Research, Israel Business Development, Life Science Nation
  • Candice He, Vice President, Business Development, Global Investment Strategist, Life Science Nation
This bootcamp is designed to help scientist-entrepreneurs navigate the world of fundraising. It starts out by debunking some commonly held misconceptions about early-stage startups and fundraising, followed by tips on how to improve your chances and increasing investor visibility.
Preparing to Pitch at RESI
  • Candice He, Vice President, Business Development, Global Investment Strategist, Life Science Nation
The Innovator’s Pitch Challenge (IPC) is an opportunity for early-stage companies to gain additional exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session. This bootcamp will walk through the process of preparing your pitch materials and what to expect in a live pitch session, including frequently asked questions from investor judges.
Strategies for Successful Partnering
  • Alexander Vassallo, Manager, Business Development, Life Science Nation
  • Joey Wong, Analyst, Investor Research, Hong Kong BD Life Science Nation
This bootcamp is a fan favorite with tried-and-true tips to make your partnering experience exceptional, letting your technology, product, and team take center-stage. Whether booking 1-on-1 meetings or pitching to a panel, these strategies will help you prioritize the details that make a difference in telling your story to potential investors and strategic partners.

Our Redefining Early Stage Investments (RESI) conference returns in a virtual format June 7-9. Register today and save $300 on super early bird rates by April 15!

Register-now-button-new

Hot Investor Mandate: Healthcare-Focused Firm Seeks to Invest Up to $50M in High Potential Clinical, Later-Stage Opportunities Close to Commercialization

A healthcare-focused Venture Capital and Growth Equity firm currently manages ~$1 billion, providing $15-$50 million of equity capital per company over the life of the investment. With offices in USA and Europe, the firm is primarily looking for companies throughout North America and Europe.

The firm is currently interested in companies in areas of medical technology, biopharmaceuticals, diagnostics, medical devices, life sciences tools, digital health, and veterinary medicine. Significant emphasis is placed on the clinical utility and health economics of potential investments. The firm focuses on later-stage opportunities that are already commercialized or are close to commercialization. The firm is open in terms of indications.

The firm looks for management teams that are very willing to work alongside them, and the firm generally looks to take a board seat. The firm is open to investing in both public and privately held companies, is open to a variety of deal structures, and can consider equity investments or buy-out opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Canada-Based Life Sciences VC Actively Seeks Therapeutics and Medical Device Investment Opportunities in North America

A life sciences venture capital firm based in Canada with additional offices in USA manages over $500M AUM and has invested over $450M in more than 100 companies. With their recent fund closed in 2021, the firm typically makes initial investments ranging from $2-$6 million of equity and looks to invest $8-$12 million over the lifetime of the investment. The firm expects to make 4-6 investments over the next 12 months, and prioritizes investment opportunities that are based in USA or Canada.

The firm invests primarily in therapeutics and  medical devices, and consumer health technologies. The firm generally looks for companies phase I and later that have at least some human proof-of-concept with either early human efficacy signs or very strong animal data coupled with human safety data. That said, the firm is open to earlier stage, pre-clinical companies with strong validation. The firm is agnostic in terms of modalities.

The firm invests in companies throughout the United States and Canada. The firm does not look to take an active role on the management team but does look to take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Global Biopharmaceutical Company Seeks Therapeutics and Medical Devices Companies With Strong Asia Market Potential For Investment, In-Licensing, and More

A global biopharmaceutical company with strong interest to invest and collaborate with clinical & early-stage life science companies has significant experience and expertise in conducting drug development and clinical trials in Asia and China, and they are looking to leverage that to partner up with clinical-stage companies. The firm is open to equity investment, licensing-in, co-development and other partnership models. In terms of equity investments, the firm typically engages in seed to series A investment rounds. The initial check size ranges from $1~ 3M with the possibility for follow-on rounds. The firm is generally interested in companies based in the US and Europe and is open to both leading and co-investing.

The firm is interested in therapeutics and medical devices that provide solutions to unmet needs and have strong market potential in Asia and China. Interested indications include chronic, inflammation and aging-related diseases, oncology, and rare diseases. The firm is also interested in rare diseases as long as there are huge unmet needs. The firm is most interested in therapeutics assets that are in Phase I or Phase II clinical stage but can be flexible if the technology is a good fit.

There are no specific requirements for the company’s management team. The firm might consider a board seat on a case-by-case basis. The firm has a strong presence in China and Asia and is willing to support companies with their expertise and experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.